This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ugurel, S. Articles by Reinhold, U. Search for Related Content PubMed PubMed Citation Articles by Ugurel, S. Articles by Reinhold, U.

Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival

From the Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany.

Address reprint requests to Uwe Reinhold, MD, Department of Dermatology, The Saarland University Hospital, 66421 Homburg/Saar, Germany; email uwe.reinhold{at}med-rz.uni-sb.de

PURPOSE: To determine the predictive value of the angiogenic serum factors angiogenin, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin-8 (IL-8) for the prognosis of patients with malignant melanoma.

PATIENTS AND METHODS: Angiogenin, VEGF, bFGF, and IL-8 were measured in sera of 125 melanoma patients with different stages of disease and with or without current therapy including interferon alfa and different cytostatics in comparison with 30 healthy controls using enzyme-linked immunosorbent assay.

RESULTS: Serum levels of angiogenin, VEGF, bFGF, and IL-8 were significantly increased in melanoma patients compared with healthy controls. Elevated serum concentrations of VEGF, bFGF, and IL-8 were associated with advanced disease stages and tumor burden. Cytostatic therapy of patients was accompanied by increased serum levels of angiogenin, bFGF, and IL-8. As shown by univariate analysis, elevated serum levels of VEGF (P = .0001 and .0036), bFGF (P < .00005 and < .00005), and IL-8 (P < .00005 and < .00005) were strongly correlated with a poor overall and progression-free survival, respectively. Multivariate analysis revealed stage of disease (P = .0238), tumor burden (P = .0347), VEGF (P = .0036), bFGF (P = .0252), and IL-8 (P = .0447) as independent predictive factors of overall survival. Tumor burden (P = .0081), VEGF (P = .0245), and IL-8 (P = .0089) were found as independent predictive factors of progression-free survival.

CONCLUSION: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients.

This article has been cited by other articles:

				M. Joao Bugalho, D. Madureira, C. Espadinha, A. Paula Font, and L. G Sobrinho Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2008; 159(2): 167 - 169. [Abstract] [Full Text] [PDF]

				S. Crawford, D. Belajic, J. Wei, J. P. Riley, P. J. Dunford, S. Bembenek, A. Fourie, J. P. Edwards, L. Karlsson, A. Brunmark, et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker Mol. Cancer Ther., March 1, 2008; 7(3): 492 - 499. [Abstract] [Full Text] [PDF]

				Y. Ding, E. A. Boguslawski, B. D. Berghuis, J. J. Young, Z. Zhang, K. Hardy, K. Furge, E. Kort, A. E. Frankel, R. V. Hay, et al. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma Mol. Cancer Ther., March 1, 2008; 7(3): 648 - 658. [Abstract] [Full Text] [PDF]

				M. L. Petreaca, M. Yao, Y. Liu, K. DeFea, and M. Martins-Green Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability Mol. Biol. Cell, December 1, 2007; 18(12): 5014 - 5023. [Abstract] [Full Text] [PDF]

				K. A. Varker, J. E. Biber, C. Kefauver, R. Jensen, A. Lehman, D. Young, H. Wu, G. B. Lesinski, K. Kendra, H. X. Chen, et al. A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma Ann. Surg. Oncol., August 1, 2007; 14(8): 2367 - 2376. [Abstract] [Full Text] [PDF]

				S. Giorgini, D. Trisciuoglio, C. Gabellini, M. Desideri, L. Castellini, C. Colarossi, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression Mol. Cancer Res., August 1, 2007; 5(8): 761 - 771. [Abstract] [Full Text] [PDF]

				B. Schwartz, O. Shoseyov, V. O. Melnikova, M. McCarty, M. Leslie, L. Roiz, P. Smirnoff, G.-f. Hu, D. Lev, and M. Bar-Eli ACTIBIND, a T2 RNase, Competes with Angiogenin and Inhibits Human Melanoma Growth, Angiogenesis, and Metastasis Cancer Res., June 1, 2007; 67(11): 5258 - 5266. [Abstract] [Full Text] [PDF]

				Z. R. Yurkovetsky, J. M. Kirkwood, H. D. Edington, A. M. Marrangoni, L. Velikokhatnaya, M. T. Winans, E. Gorelik, and A. E. Lokshin Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-{alpha}2b Clin. Cancer Res., April 15, 2007; 13(8): 2422 - 2428. [Abstract] [Full Text] [PDF]

				J. M. Shields, N. E. Thomas, M. Cregger, A. J. Berger, M. Leslie, C. Torrice, H. Hao, S. Penland, J. Arbiser, G. Scott, et al. Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma Cancer Res., February 15, 2007; 67(4): 1502 - 1512. [Abstract] [Full Text] [PDF]

				J. A. Sosman and I. Puzanov Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s. [Abstract] [Full Text] [PDF]

				S. Hirukawa, K. A. Olson, T. Tsuji, and G.-f. Hu Neamine Inhibits Xenografic Human Tumor Growth and Angiogenesis in Athymic Mice Clin. Cancer Res., December 15, 2005; 11(24): 8745 - 8752. [Abstract] [Full Text] [PDF]

				T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge, and L. Cheng Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors Clin. Cancer Res., December 1, 2005; 11(23): 8358 - 8363. [Abstract] [Full Text] [PDF]

				S. Mian, S. Ugurel, E. Parkinson, I. Schlenzka, I. Dryden, L. Lancashire, G. Ball, C. Creaser, R. Rees, and D. Schadendorf Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients J. Clin. Oncol., August 1, 2005; 23(22): 5088 - 5093. [Abstract] [Full Text] [PDF]

				P. L. Triozzi, K. O. Allen, R. R. Carlisle, M. Craig, A. F. LoBuglio, and R. M. Conry Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma Clin. Cancer Res., June 1, 2005; 11(11): 4168 - 4175. [Abstract] [Full Text] [PDF]

				J. L. Formento, E. Berra, B. Ferrua, N. Magne, G. Simos, C. Brahimi-Horn, J. Pouyssegur, and G. Milano Enzyme-Linked Immunosorbent Assay for Pharmacological Studies Targeting Hypoxia-Inducible Factor 1{alpha} Clin. Vaccine Immunol., May 1, 2005; 12(5): 660 - 664. [Abstract] [Full Text] [PDF]

				W. Li, P. Kessler, H. Yeger, J. Alami, A. E. Reeve, R. Heathcott, J. Skeen, and B. R.G. Williams A Gene Expression Signature for Relapse of Primary Wilms Tumors Cancer Res., April 1, 2005; 65(7): 2592 - 2601. [Abstract] [Full Text] [PDF]

				I. H. Benoy, R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, S. Scharpe, P. B. Vermeulen, and L. Y. Dirix Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival Clin. Cancer Res., November 1, 2004; 10(21): 7157 - 7162. [Abstract] [Full Text] [PDF]

				Y. Ren, R. T.-P. Poon, H.-T. Tsui, W.-H. Chen, Z. Li, C. Lau, W.-C. Yu, and S.-T. Fan Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis Clin. Cancer Res., December 1, 2003; 9(16): 5996 - 6001. [Abstract] [Full Text] [PDF]

				D. C. Lev, M. Ruiz, L. Mills, E. C. McGary, J. E. Price, and M. Bar-Eli Dacarbazine Causes Transcriptional Up-Regulation of Interleukin 8 and Vascular Endothelial Growth Factor in Melanoma Cells: A Possible Escape Mechanism from Chemotherapy Mol. Cancer Ther., August 1, 2003; 2(8): 753 - 763. [Abstract] [Full Text] [PDF]

				B. C. Kuenen, J. Tabernero, J. Baselga, F. Cavalli, E. Pfanner, P. F. Conte, S. Seeber, S. Madhusudan, G. Deplanque, H. Huisman, et al. Efficacy and Toxicity of the Angiogenesis Inhibitor SU5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma, Melanoma, and Soft Tissue Sarcoma Clin. Cancer Res., May 1, 2003; 9(5): 1648 - 1655. [Abstract] [Full Text] [PDF]

				P. Lu, Y. Nakamoto, Y. Nemoto-Sasaki, C. Fujii, H. Wang, M. Hashii, Y. Ohmoto, S. Kaneko, K. Kobayashi, and N. Mukaida Potential Interaction between CCR1 and Its Ligand, CCL3, Induced by Endogenously Produced Interleukin-1 in Human Hepatomas Am. J. Pathol., April 1, 2003; 162(4): 1249 - 1258. [Abstract] [Full Text] [PDF]

				M. P. Malafa, F. D. Fokum, L. Smith, and A. Louis Inhibition of Angiogenesis and Promotion of Melanoma Dormancy by Vitamin E Succinate Ann. Surg. Oncol., December 1, 2002; 9(10): 1023 - 1032. [Abstract] [Full Text] [PDF]

				T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1492 - 1495. [Abstract] [Full Text] [PDF]

				S. H. Smith, M. H. Goldschmidt, and P. M. McManus A Comparative Review of Melanocytic Neoplasms Vet. Pathol., November 1, 2002; 39(6): 651 - 678. [Abstract] [Full Text] [PDF]

				H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer Cancer Res., September 15, 2002; 62(18): 5210 - 5217. [Abstract] [Full Text] [PDF]

				E. S. J. M. de Bont, V. Fidler, T. Meeuwsen, F. Scherpen, K. Hahlen, and W. A. Kamps Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients Clin. Cancer Res., September 1, 2002; 8(9): 2856 - 2861. [Abstract] [Full Text] [PDF]

				R. Y. T. Kao, J. L. Jenkins, K. A. Olson, M. E. Key, J. W. Fett, and R. Shapiro A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity PNAS, July 23, 2002; 99(15): 10066 - 10071. [Abstract] [Full Text] [PDF]

				S. Huang, L. Mills, B. Mian, C. Tellez, M. McCarty, X.-D. Yang, J. M. Gudas, and M. Bar-Eli Fully Humanized Neutralizing Antibodies to Interleukin-8 (ABX-IL8) Inhibit Angiogenesis, Tumor Growth, and Metastasis of Human Melanoma Am. J. Pathol., July 1, 2002; 161(1): 125 - 134. [Abstract] [Full Text] [PDF]

				R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742. [Abstract] [Full Text] [PDF]

				K. Satyamoorthy, G. Li, B. Vaidya, J. Kalabis, and M. Herlyn Insulin-like Growth Factor-I-induced Migration of Melanoma Cells Is Mediated by Interleukin-8 Induction Cell Growth Differ., February 1, 2002; 13(2): 87 - 93. [Abstract] [Full Text] [PDF]

				F. J. Giles The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 32 - 39. [Abstract] [Full Text] [PDF]

				O. Sezer, C. Jakob, K. Niemoller, R. T.P. Poon, S.-T. Fan, and J. Wong Angiogenesis in Cancer J. Clin. Oncol., July 1, 2001; 19(13): 3299 - 3301. [Full Text]